Name 5 cell cycle specific agents.
- antimetabolites
- bleomycin
- microtubule inhibitors
- epipodophyllotoxins
- camptothecins
Name 3 cycle-nonspecific agents.
- alkylating agents
- platinum coordination complexes
- antitumor antibiotics
P-glycoprotein is over expressed in multi-drug resistance. Name 6 drugs responsible for this.
- doxorubicin
- daunorubicin
- vincristine
- vinblastine
- etoposide
- tenoposide
Name 5 drugs with HIGH relative myelosuppression
- cytarabine
- alkylating agents
- doxorubicin
- daunorubicin
- vinblastine
Name 3 drugs with MEDIUM relative myelosuppression
- carboplatin
- methotrexate
- 5-FU (fluoro-uracil)
Name 3 drugs with LOW relative myelosuppression
- bleomycin
- vincristine
- asparaginase
common adverse effects.
Doxorubicin
cardiotoxicity
common adverse effects.
Cyclophosphamide
- hemorrhagic cystitis (reduced with Mesna)
- blood in urine
common adverse effects.
Bleomycin
pulmonary fibrosis
common adverse effects.
Vincristine
peripheral neuropathy
common adverse effects.
Paclitaxel
(a microtubule inhibitor)
peripheral neuropathy
minimizing adverse effects.
5HT3 receptor blockers and NK-1 inhibitors
manage chemotherapy-induced emesis
minimizing adverse effects.
Filgrastim and Sargramotism
used in the prevention and treatment of chemotherapy-induced neutropenia
minimizing adverse effects.
Leucovorin
an antidote given at the same time that methotrexate is given- to rescue bone marry from myelosuppression
minimizing adverse effects.
Mesna
reduces hemorrhagic cystitis caused by Cyclophophamide
minimizing adverse effects.
Dexrazoxane
reduces Anthracycline induced cardio toxicity
minimizing adverse effects.
Amifostine
(given as an adjuvant)
-reduces renal toxicity caused by Cisplatin
